NCT04274166View on ClinicalTrials.gov

Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

April 30, 2022

Conditions
Pyoderma Gangrenosum
Interventions
DRUG

secukinumab 150 mg (2 injections per dose

secukinumab 150 mg (2 injections per dose

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Wake Forest University Health Sciences

OTHER

NCT04274166 - Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum | Biotech Hunter | Biotech Hunter